Solventum Co. (NYSE:SOLV) is Rudius Management LP's 7th Largest Position

Rudius Management LP reduced its position in Solventum Co. (NYSE:SOLV - Free Report) by 39.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,427 shares of the company's stock after selling 40,000 shares during the period. Solventum makes up approximately 0.9% of Rudius Management LP's holdings, making the stock its 7th largest holding. Rudius Management LP's holdings in Solventum were worth $4,283,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Tokio Marine Asset Management Co. Ltd. increased its position in shares of Solventum by 4.2% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company's stock worth $346,000 after acquiring an additional 200 shares during the last quarter. National Bank of Canada FI raised its holdings in Solventum by 4.0% in the second quarter. National Bank of Canada FI now owns 6,093 shares of the company's stock valued at $314,000 after acquiring an additional 236 shares in the last quarter. IVC Wealth Advisors LLC boosted its stake in Solventum by 5.0% during the 3rd quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company's stock valued at $464,000 after acquiring an additional 318 shares during the last quarter. KKM Financial LLC grew its holdings in Solventum by 7.9% during the 3rd quarter. KKM Financial LLC now owns 4,367 shares of the company's stock worth $304,000 after acquiring an additional 319 shares in the last quarter. Finally, Copeland Capital Management LLC bought a new stake in shares of Solventum in the 3rd quarter worth about $26,000.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. BTIG Research started coverage on Solventum in a research note on Thursday, September 5th. They issued a "neutral" rating for the company. Wells Fargo & Company lowered their price target on Solventum from $69.00 to $64.00 and set an "equal weight" rating for the company in a report on Friday, August 9th. Wolfe Research assumed coverage on shares of Solventum in a research note on Thursday, September 26th. They set a "peer perform" rating for the company. Morgan Stanley raised their price target on shares of Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a research report on Monday, November 11th. Finally, The Goldman Sachs Group raised their target price on shares of Solventum from $48.00 to $54.00 and gave the stock a "sell" rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. According to MarketBeat, Solventum currently has an average rating of "Hold" and an average price target of $68.00.

Solventum Price Performance

Solventum stock opened at $71.50 on Wednesday. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The firm has a 50 day simple moving average of $70.51 and a 200-day simple moving average of $62.40. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.